FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
DiaSorin S.p.A. Stock AnalysisComprehensive stock analysis for DiaSorin S.p.A. (DSRLF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisDSRLF
DSRLF
DiaSorin S.p.A.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
DSRLF
Home🔹Stocks🔹DiaSorin S.p.A.

DiaSorin S.p.A.

DSRLF•OTC

DiaSorin S.p.A.

DSRLF•OTC
Market cap
$4.49B
Sentiment

Your view on DSRLF

Mkt Cap
$4.49B
Sentiment
Your view
DSRLF
DiaSorin S.p.A.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
DSRLF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About DiaSorin S.p.A.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
CEO
Carlo Rosa
Headquarters
Via Crescentino snc, Saluggia, VC, IT
Industry
Medical - Diagnostics & Research
Sector
Healthcare
CEO
Carlo Rosa
Headquarters
Via Crescentino snc, Saluggia, VC, IT
Description

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News